Database : MEDLINE
Search on : pulmonary and eosinophilia [Words]
References found : 5779 [refine]
Displaying: 1 .. 10   in format [Detailed]

page 1 of 578 go to page                         

  1 / 5779 MEDLINE  
              next record last record
select
to print
Photocopy
Full text

[PMID]: 29200850
[Au] Autor:Aliu H; Rask C; Brimnes J; Andresen TL
[Ad] Address:Immunology Department, In vivo Biology Team, ALK Abelló A/S, Hørsholm.
[Ti] Title:Enhanced efficacy of sublingual immunotherapy by liposome-mediated delivery of allergen.
[So] Source:Int J Nanomedicine;12:8377-8388, 2017.
[Is] ISSN:1178-2013
[Cp] Country of publication:New Zealand
[La] Language:eng
[Ab] Abstract:Immunotherapy by sublingual administration of allergens provides high patient compliance and has emerged as an alternative to subcutaneous immunotherapy for the treatment of IgE-associated allergic diseases. However, sublingual immunotherapy (SLIT) can cause adverse events. Development of allergen delivery systems enabling more efficient delivery and hence lower allergen load might reduce the adverse events. In the present study, we have investigated neutral and cationic liposomes as delivery systems of ovalbumin (OVA), as a model allergen, in an OVA-induced allergic airway inflammation model. We investigated the liposome carriers' ability to improve tolerance induction of antigens compared to the corresponding dose of free OVA. Mice were treated sublingually over 2 weeks with free or liposome encapsulated OVA followed by intraperitoneal injections and intranasal challenge. Mice sublingually treated with OVA-liposomes showed a significant reduction of airway eosinophilia and splenocyte proliferation in comparison to free OVA. A similar nonsignificant pattern was seen for OVA-specific IgE antibodies. In addition, reduced levels of interferon-γ and interleukin-5 were observed in spleen cell culture supernatants from OVA-liposome-treated mice compared to the sham-treated group. In conclusion, in vivo efficacy data showed that prophylactic SLIT with OVA-liposomes is significantly more effective in preventing allergic inflammation than the corresponding dose of free OVA.
[Mh] MeSH terms primary: Allergens/administration & dosage
Drug Delivery Systems
Sublingual Immunotherapy
[Mh] MeSH terms secundary: Allergens/immunology
Animals
Cytokines/metabolism
Enzyme-Linked Immunosorbent Assay
Female
Lipids/chemistry
Liposomes
Mice, Inbred BALB C
Ovalbumin/immunology
Pneumonia/immunology
Pneumonia/pathology
Pneumonia/prevention & control
Spleen/immunology
[Pt] Publication type:JOURNAL ARTICLE
[Nm] Name of substance:0 (Allergens); 0 (Cytokines); 0 (Lipids); 0 (Liposomes); 9006-59-1 (Ovalbumin)
[Em] Entry month:1803
[Cu] Class update date: 180309
[Lr] Last revision date:180309
[Js] Journal subset:IM
[Da] Date of entry for processing:171205
[St] Status:MEDLINE
[do] DOI:10.2147/IJN.S137033

  2 / 5779 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29256215
[Au] Autor:Park TY; Jung JW; Jang JY; Choi JC; Shin JW; Park IW; Choi BW; Kim JY
[Ad] Address:Department of Internal Medicine, Chung-Ang University College of Medicine, Seoul, Korea.
[Ti] Title:Peripheral Eosinophilia and Clinico-radiological Characteristics among Health Screening Program Recipients.
[So] Source:Tuberc Respir Dis (Seoul);, 2017 Nov 27.
[Is] ISSN:1738-3536
[Cp] Country of publication:Korea (South)
[La] Language:eng
[Ab] Abstract:BACKGROUND: Eosinophilia is well recognized in specific conditions. The objective of the present study was to determine clinico-radiologic characteristics of eosinophilia and changes in prevalence over 10 years in recipients of private health screening program at a tertiary hospital in Korea. METHODS: Data of private health screening program recipients at the health promotion center of Chung-Ang University Hospital from 2004 to 2013 were collected. Health-related questionnaires and laboratory findings of private health screening program with possible relation with eosinophilia were reviewed. Results of enzyme-linked immunosorbent assay (ELISA) for parasite, chest computed tomography, and pulmonary function test were also reviewed. RESULTS: The cumulative prevalence of eosinophilia was 4.0% (1,963 of 48,928). Prevalence of eosinophilia showed a decreased trend from 2004 to 2013. Most cases (96.6%) had mild degree of eosinophilia. Eosinophilic subjects were older and male-predominant. They showed lower levels of forced expiratory volume in 1 second (FEV1%), forced vital capacity (FVC%), and FEV1/FVC than those without eosinophilia. Eosinophilic subjects showed higher positive rate for common parasite in ELISA than those without eosinophilia. On radiologic findings, consolidation and ground glass opacities were positively associated with the degree of eosinophilia. When eosinophil was classified based on severity, statistically significant correlation between the severity of eosinophil and radiologic abnormalities was found. CONCLUSION: Eosinophilia is uncommon in healthy population. It usually occurs at a mild degree. Eosinophilic patients have more radiologic abnormalities compared to those without eosinophilia. Such radiologic abnormalities are associated with the severity of eosinophilia.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1712
[Cu] Class update date: 180308
[Lr] Last revision date:180308
[St] Status:Publisher
[do] DOI:10.4046/trd.2017.0039

  3 / 5779 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29229474
[Au] Autor:Pérez de Llano L; Cosío BG; Miravitlles M; Plaza V; CHACOS study group
[Ad] Address:Department of Respiratory Medicine, Hospital Lucus Augusti, Lugo, Spain. Electronic address: eremos26@hotmail.com.
[Ti] Title:Accuracy of a New Algorithm to Identify Asthma-COPD Overlap (ACO) Patients in a Cohort of Patients with Chronic Obstructive Airway Disease.
[So] Source:Arch Bronconeumol;, 2017 Dec 09.
[Is] ISSN:1579-2129
[Cp] Country of publication:Spain
[La] Language:eng; spa
[Ab] Abstract:OBJECTIVES: We aimed to characterize the clinical, functional and inflammatory features of patients diagnosed diagnosed with ACO according to a new algorithm and to compare them with those of other chronic obstructive airway disease (COAD) categories (asthma and COPD). METHODS: ACO was diagnosed in a cohort of COAD patients in those patients with COPD who were either diagnosed with current asthma or showed significant blood eosinophilia (≥300cells/µl) and/or a very positive bronchodilator response (>400ml and >15% in FEV1). RESULTS: Eighty-seven (29.8%) out of 292 patients fulfilled the ACO diagnostic criteria (12.8% asthmatics who smoked <20 pack-years, 100% of asthmatics who smoked ≥20 pack-years, 47.7% of COPD with >200eosinophils/µl in blood and none with non-eosinophilic COPD). ACO, asthma and COPD patients showed no differences in symptoms or exacerbation rate. Mean pre-bronchodilator FEV1 in ACO and asthma were similar (1741 vs 1771ml), higher than in COPD (1431ml, p<0.05). DLCO was lower in ACO than in asthma (68.1 vs 84.1%) and similar to COPD (64.5%). Mean blood eosinophil count was similar in ACO and asthma (360 vs 305cells/µl) and higher than in COPD (170cells/µl). Periostin levels were similar in ACO to COPD (36.6 and 36.5IU/ml) and lower than in asthma (41.5IU/ml, p<0.05), whereas FeNO levels in ACO were intermediate. CONCLUSION: This algorithm classifies as ACO all smoking asthmatics with non-fully reversible airway obstruction and a considerable proportion of e-COPD patients, highlighting those who can benefit from inhaled corticosteroids.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1712
[Cu] Class update date: 180304
[Lr] Last revision date:180304
[St] Status:Publisher

  4 / 5779 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29393212
[Au] Autor:Ito Y; Schaefer N; Sanchez A; Francisco D; Alam R; Martin RJ; Ledford JG; Stevenson C; Jiang D; Li L; Kraft M; Chu HW
[Ad] Address:Department of Medicine, National Jewish Health, Denver, CO, USA.
[Ti] Title:Toll-Interacting Protein, Tollip, Inhibits IL-13-Mediated Pulmonary Eosinophilic Inflammation in Mice.
[So] Source:J Innate Immun;, 2018 Jan 27.
[Is] ISSN:1662-8128
[Cp] Country of publication:Switzerland
[La] Language:eng
[Ab] Abstract:Toll-interacting protein (Tollip) is a key negative regulator of innate immunity by preventing excessive proinflammatory responses. Tollip genetic variation has been associated with airflow limitation in asthma subjects and Tollip expression. Whether Tollip regulates lung inflammation in a type 2 cytokine milieu (e.g., IL-13) is unclear. Our goal was to determine the in vivo role of Tollip in IL-13-mediated lung eosinophilic inflammation and the underlying mechanisms. Tollip-knockout (KO) and wild-type (WT) mice were inoculated intranasally with recombinant mouse IL-13 protein to examine lung inflammation. To determine how Tollip regulates inflammation, alveolar macrophages and bone marrow-derived macrophages from Tollip KO and WT mice were cultured with or without IL-13 and/or IL-33. IL-13-treated Tollip KO mice significantly increased lung eosinophilic inflammation and eotaxin-2 (CCL24) levels compared with the WT mice. IL-13- treated Tollip KO (vs. WT) macrophages, in the absence and particularly in the presence of IL-33, increased expression of the IL-33 receptor ST2L and CCL24, which was in part dependent on enhanced activation of interleukin (IL)-1 receptor-associated kinase 1 (IRAK1) and signal transducer and activator of transcription 6 (STAT6). Our results suggest that Tollip downregulates IL-13-mediated pulmonary eosinophilia in part through inhibiting the activity of the ST2L/IL-33/IRAK1 axis and STAT6.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1802
[Cu] Class update date: 180303
[Lr] Last revision date:180303
[St] Status:Publisher
[do] DOI:10.1159/000485850

  5 / 5779 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29483774
[Au] Autor:de Llano LP; Cosío BG; Iglesias A; de Las Cuevas N; Soler-Cataluña JJ; Izquierdo JL; López-Campos JL; Calero C; Plaza V; Miravitlles M; Torrego A; Martinez-Moragon E; Soriano JB; Viña AL; Bobolea I
[Ad] Address:Department of Respiratory Medicine, Hospital Lucus Augusti, Lugo, Spain.
[Ti] Title:Mixed Th2 and non-Th2 inflammatory pattern in the asthma-COPD overlap: a network approach.
[So] Source:Int J Chron Obstruct Pulmon Dis;13:591-601, 2018.
[Is] ISSN:1178-2005
[Cp] Country of publication:New Zealand
[La] Language:eng
[Ab] Abstract:Introduction: The asthma-chronic obstructive pulmonary disease (COPD) overlap (ACO) is a clinical condition that combines features of those two diseases, and that is difficult to define due to the lack of understanding of the underlying mechanisms. Determining systemic mediators may help clarify the nature of inflammation in patients with ACO. Objectives: We aimed at investigating the role and interaction of common markers of systemic inflammation (IL-6, IL-8, and tumor necrosis factor-α), Th2-related markers (periostin, IL-5, and IL-13), and IL-17 in asthma, COPD, and ACO. Methods: This is a cross-sectional study of patients aged ≥40 years with a post-bronchodilator forced expiratory volume in the first second/forced vital capacity <0.70 recruited from outpatient clinics in tertiary hospitals with a clinical diagnosis of asthma, COPD, or ACO. ACO was defined by a history of smoking >10 pack-years in a patient with a previous diagnosis of asthma or by the presence of eosinophilia in a patient with a previous diagnosis of COPD. Clinical, functional, and inflammatory parameters were compared between categories using discriminant and network analysis. Results: In total, 109 ACO, 89 COPD, and 94 asthma patients were included. Serum levels (median [interquartile range]) of IL-5 were higher in asthma patients than in COPD patients (2.09 [0.61-3.57] vs 1.11 [0.12-2.42] pg/mL, respectively; =0.03), and IL-8 levels (median [interquartile range]) were higher in COPD patients than in asthma patients (9.45 [6.61-13.12] vs 7.03 [4.69-10.44] pg/mL, respectively; <0.001). Their values in ACO were intermediate between those in asthma and in COPD. Principal component and network analysis showed a mixed inflammatory pattern in ACO in between asthma and COPD. IL-13 was the most connected node in the network, with different weights among the three conditions. Conclusion: Asthma and COPD are two different inflammatory conditions that may overlap in some patients, leading to a mixed inflammatory pattern. IL-13 could be central to the regulation of inflammation in these conditions.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1802
[Cu] Class update date: 180301
[Lr] Last revision date:180301
[St] Status:In-Data-Review
[do] DOI:10.2147/COPD.S153694

  6 / 5779 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29253843
[Au] Autor:Low EV; Hughes SM; Zaffarullah S; Kantas D; Stockley RA; Turner AM
[Ad] Address:Heart of England NHS Foundation Trust, Birmingham, United Kingdom.
[Ti] Title:ICS Use May Modify FEV1 Decline in α1-Antitrypsin Deficiency Patients with Relatively High Blood Eosinophils.
[So] Source:Respiration;95(2):114-121, 2018.
[Is] ISSN:1423-0356
[Cp] Country of publication:Switzerland
[La] Language:eng
[Ab] Abstract:BACKGROUND: α1-Antitrypsin deficiency (AATD) predisposes to chronic obstructive pulmonary disease (COPD). In COPD unrelated to AATD, the role of a higher blood eosinophil count in disease and subsequent personalization of therapy has recently received much attention. We sought to investigate this concept in patients with AATD-associated COPD. OBJECTIVES: The study aims to evaluate eosinophilia status against outcomes including mortality and FEV1 decline in patients with AATD. METHODS: All patients with PiSZ and PiZZ genotypes were identified from the UK AATD registry. The participants were substratified according to inhaled corticosteroid (ICS) use. Blood eosinophil counts were assessed from baseline and annually during follow-up (range 1-18 years). Eosinophilia was defined as a level >0.2 × 109/L, and classified by the frequency of such counts into "always," "intermittent," or "never present." Univariate and multivariate analyses were conducted. RESULTS: In total, 646 participants were included, 53.9% of whom demonstrated intermittent and 7.4% persistent eosinophilia. Survival did not differ according to eosinophilic group (p > 0.05). Those with persistent eosinophilia showed a slower FEV1 decline (p < 0.001). There was no clear association with exacerbation frequency. Patients on ICS at baseline were more likely to be eosinophilic (p = 0.002) and having a lower FEV1 (p < 0.001) and greater pack-year exposure (16.5 vs. 7.8 pack-years, p < 0.001). When the multivariate analyses of FEV1 decline were stratified for baseline ICS use, the association of persistent eosinophilia with slower decline persisted in those on ICS. CONCLUSIONS: Blood eosinophil levels persistently >0.2 × 109/L may be an indication for ICS use in PiZZ AATD in order to reduce FEV1 decline.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1712
[Cu] Class update date: 180227
[Lr] Last revision date:180227
[St] Status:In-Data-Review
[do] DOI:10.1159/000481867

  7 / 5779 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29477568
[Au] Autor:Qiu R; Xie J; Chung KF; Li N; Yang Z; He M; Li J; Chen R; Zhong N; Zhang Q
[Ad] Address:Department of Allergy and Clinical Immunology, State Key Laboratory of Respiratory Diseases, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China;; The Affiliated Ganzhou
[Ti] Title:Asthma phenotypes defined from parameters obtained during recovery from a hospital-treated exacerbation.
[So] Source:J Allergy Clin Immunol Pract;, 2018 Feb 22.
[Is] ISSN:2213-2201
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:BACKGROUND: Asthma is a heterogeneous disease with diverse clinical manifestations and inflammatory pathologies that is punctuated by exacerbations. OBJECTIVES: To describe the clinical and inflammatory characteristics of asthma patients treated in hospital for an acute exacerbation. METHODS: Data from 320 adult patients receiving treatment for an acute exacerbation of asthma were obtained. In 218 with complete data , we used Ward's hierarchical clustering to obtain clusters. Pulmonary function, blood counts, sputum cell counts, serum IgE levels, and fractional exhaled nitric oxide were measured during the hospital admission. We selected 13 variables with which we performed Ward's minimum variance hierarchical clustering. RESULTS: Four clusters were defined. Clusters 1(24.5%) and 3(36.7%) were characterized by predominantly-female asthmatics with sputum neutrophilia, with Cluster 1 associated with small degree of airflow obstruction and early onset of asthma while Cluster 3 had a moderate degree of reduction in FEV . Clusters 2(22.0%) and 4(16.5%) were associated with high sputum eosinophilia and severe airflow obstruction, but Cluster 4 was made up exclusively of male smoking subjects while Cluster 2 of predominantly female non-smoking subjects with the worst FEV , FEF (% predicted) and arterial partial pressure of oxygen (PaO ) on admission. There were no differences between clusters in terms of atopy, serum IgE, prevalence of nasal disease, maintenance inhaled corticosteroids, or oral/systemic corticosteroid use and asthma exacerbations. CONCLUSION: The clusters during recovery from an exacerbation of asthma were distinguished by airflow obstruction and a neutrophilic, eosinophilic or mixed inflammation. Eosinophilic inflammation was found in smoking and non-smoking asthmatics during an exacerbation.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1802
[Cu] Class update date: 180225
[Lr] Last revision date:180225
[St] Status:Publisher

  8 / 5779 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29464664
[Au] Autor:Markham A
[Ad] Address:Springer, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. dru@adis.com.
[Ti] Title:Benralizumab: First Global Approval.
[So] Source:Drugs;, 2018 Feb 20.
[Is] ISSN:1179-1950
[Cp] Country of publication:New Zealand
[La] Language:eng
[Ab] Abstract:Kyowa Hakko Kirin, AstraZeneca and subsidiaries are developing benralizumab (Fasenra™)-a humanised anti-interleukin-5 receptor alpha chain (IL-5Rα) monoclonal antibody-as a treatment of severe eosinophilic asthma and chronic obstructive pulmonary disease (COPD). Eosinophilia is a characteristic of certain asthma and COPD phenotypes and depletion of eosinophils has demonstrated therapeutic benefit. Benralizumab was recently approved by the US FDA as add-on maintenance therapy for patients with severe asthma who have an eosinophilic phenotype. This article summarizes the milestones in the development of benralizumab leading to this first approval for the treatment of severe eosinophilic asthma.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1802
[Cu] Class update date: 180226
[Lr] Last revision date:180226
[St] Status:Publisher
[do] DOI:10.1007/s40265-018-0876-8

  9 / 5779 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29429561
[Au] Autor:Kombila UD; Ka W; Mbaye FBR; Diouf NF; Fall L; Ouedraogo P; Koutonin ANE; Dia Kane Y; Oumar Toure Badiane N
[Ad] Address:Service de médecine interne, centre hospitalier universitaire de Libreville (CHUL), BP 9264, Libreville, Gabon; Clinique de pneumologie, centre hospitalier national universitaire de FANN (CHNUF), avenue Cheikh-ANTA-DIOP, BP 5035, Dakar, Sénégal. Electronic address: ukombila@yahoo.fr.
[Ti] Title:DRESS syndrome au pyrazinamide : complication rare et grave du traitement antituberculeux. [DRESS syndrome secondary to pyrazinamide: An uncommon complication of tuberculosis treatment].
[So] Source:Rev Mal Respir;35(1):69-73, 2018 Jan.
[Is] ISSN:1776-2588
[Cp] Country of publication:France
[La] Language:fre
[Ab] Abstract:INTRODUCTION: The Drug Reaction with Eosinophilia and Systemic Symptom (DRESS) is a severe drug-induced reaction. CASE REPORT: We report the case of a 35-year-old man treated by RHEZ for a first episode of a smear positive pulmonary tuberculosis and who developed a DRESS syndrome due to pyrazinamide after twenty days of treatment, associated with a viral reactivation to Human Herpes Virus 6 (HHV6). He had a skin eruption, liver involvement and hypereosinophilia. He fully recovered after drug withdrawal, associated with local and general corticosteroids. He died two weeks after discharge. CONCLUSIONS: Discovery of DRESS syndrome during tuberculosis treatment is an uncommon complication and requires a searching for the responsible drug. That should be difficult because tuberculosis drugs are often given as fixed-dose combination. Physicians have to bear in mind the potential role of pyrazinamide.
[Pt] Publication type:ENGLISH ABSTRACT; JOURNAL ARTICLE
[Em] Entry month:1802
[Cu] Class update date: 180219
[Lr] Last revision date:180219
[St] Status:In-Process

  10 / 5779 MEDLINE  
              first record previous record
select
to print
Photocopy
Full text

[PMID]: 29338973
[Au] Autor:Padrão E; Araújo D; Todo Bom A; Robalo Cordeiro C; Correia de Sousa J; Cardoso J; Morais-Almeida M; Costa R; Pavão F; Leite RB; Marques A
[Ad] Address:Institute of Health Sciences, Universidade Católica Portuguesa, Portugal; Pulmonology Department, Centro Hospitalar de São João, Porto, Portugal. Electronic address: eva.padrao@gmail.com.
[Ti] Title:Asthma-COPD overlap: A Portuguese survey.
[So] Source:Rev Port Pneumol (2006);, 2018 Jan 12.
[Is] ISSN:2173-5115
[Cp] Country of publication:Spain
[La] Language:eng
[Ab] Abstract:INTRODUCTION: The overlap between asthma and chronic obstructive pulmonary disease (COPD) (ACO) has been discussed for many years but clinical recommendations for this entity have been diverse. This study is intended to reach a consensus on diagnosis, treatment and patient orientation for ACO, within the Portuguese medical community. METHODS: This study was conducted by a multidisciplinary panel of experts from three distinct medical specialties (Pulmonology, Family Medicine and Immunoallergology). This panel selected a total of 190 clinicians, based on their expertise in obstructive airway diseases, to participate in a Delphi structured survey with three rounds of questionnaires. These results were ultimately discussed, in a meeting with the panel of experts and some of the study participants, and consensus was reached in terms of classification criteria, treatment and orientation of ACO patients. RESULTS: The majority of clinicians (87.2%) considered relevant the definition of an overlap entity between asthma and COPD. A consensus was achieved on the diagnosis of ACO - presence of simultaneous clinical characteristics of asthma and COPD together with a fixed airflow obstruction (FEV1/FVC<0.7) associated with 2 major criteria (previous history of asthma; presence of a previous history of smoking exposure and/or exposure to biomass combustion; positive bronchodilation test (increase in FEV of at least 200mL and 12%) on more than 1 occasion) plus 1 minor criteria (history of atopy; age ≥40 years; peripheral eosinophilia (>300eosinophils/µL or >5% of leukocytes); elevation of specific IgEs or positive skin tests for common allergens). A combination of inhaled corticosteroid (ICS) with long-acting beta2-agonist (LABA) or long-acting muscarinic antagonist (LAMA) was considered as first line pharmacological treatment. Triple therapy with ICS plus LABA and LAMA should be used in more severe or symptomatic cases. Non-pharmacological treatment, similar to what is recommended for asthma and COPD, was also considered highly important. A hospital referral of ACO patients should be made in symptomatic or severe cases or when there is a lack of diagnostic resources. CONCLUSIONS: This study highlights the relevance of defining ACO, within the Portuguese medical community, and establishes diagnostic criteria that are important for future interventional studies. Recommendations on treatment and patient's orientation were also achieved.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1801
[Cu] Class update date: 180217
[Lr] Last revision date:180217
[St] Status:Publisher


page 1 of 578 go to page                         
   


Refine the search
  Database : MEDLINE Advanced form   

    Search in field  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/PAHO/WHO - Latin American and Caribbean Center on Health Sciences Information